RNAC vs. RAPT, IMAB, OPTN, RENB, MCRB, CRVS, CYBN, SYRS, KPTI, and CTMX
Should you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include RAPT Therapeutics (RAPT), I-Mab (IMAB), OptiNose (OPTN), Renovaro (RENB), Seres Therapeutics (MCRB), Corvus Pharmaceuticals (CRVS), Cybin (CYBN), Syros Pharmaceuticals (SYRS), Karyopharm Therapeutics (KPTI), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical preparations" industry.
Cartesian Therapeutics (NASDAQ:RNAC) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, community ranking, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.
Cartesian Therapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, RAPT Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.
RAPT Therapeutics received 80 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cartesian Therapeutics an outperform vote while only 66.17% of users gave RAPT Therapeutics an outperform vote.
RAPT Therapeutics has lower revenue, but higher earnings than Cartesian Therapeutics.
Cartesian Therapeutics currently has a consensus price target of $45.00, suggesting a potential upside of 70.26%. RAPT Therapeutics has a consensus price target of $24.67, suggesting a potential upside of 510.56%. Given RAPT Therapeutics' higher possible upside, analysts clearly believe RAPT Therapeutics is more favorable than Cartesian Therapeutics.
In the previous week, Cartesian Therapeutics had 2 more articles in the media than RAPT Therapeutics. MarketBeat recorded 9 mentions for Cartesian Therapeutics and 7 mentions for RAPT Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.84 beat RAPT Therapeutics' score of -0.02 indicating that Cartesian Therapeutics is being referred to more favorably in the media.
86.9% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of RAPT Therapeutics shares are owned by institutional investors. 31.2% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 6.6% of RAPT Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
RAPT Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -983.93%. Cartesian Therapeutics' return on equity of -58.21% beat RAPT Therapeutics' return on equity.
Summary
Cartesian Therapeutics beats RAPT Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Cartesian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cartesian Therapeutics Competitors List
Related Companies and Tools
